Literature DB >> 29876746

The safety of fertility preservation for microinvasive cervical adenocarcinoma: a meta-analysis and trial sequential analysis.

Ying Feng1, Zihan Zhang1, Tong Lou1, Shuzhen Wang1, Huimin Bai2, Zhenyu Zhang3.   

Abstract

PURPOSE: This study sought to evaluate the safety of conservative treatment in the management of patients with microinvasive cervical adenocarcinoma.
METHODS: The PubMed, PMC, EMBASE, Web of Science and Cochrane databases were searched to collect correlational studies published in English between January 1949 and May 2018. Series reports that evaluating the oncological prognoses of patients with microinvasive cervical adenocarcinoma who were treated with fertility-sparing surgery versus hysterectomy were pooled for meta-analysis and trial sequential analysis.
RESULTS: A total of 8 articles with 1256 patients were collected, including 7 retrospective reviews and 1 prospective study. Only one (0.08%) patient had parametrial involvement. Positive margins of surgical specimens were identified in 6 patients (2.2%). Lymph node metastasis was found in 5 patients (0.4%). The progression-free survival and overall survival rates were 99.3 and 98.2%. Fertility-sparing surgery had no adverse impact on recurrence or survival (P = 0.524 and 0.485, respectively). Regarding potential selection bias, significantly more patients with stage IA2 tumors than those with stage IA1 disease were treated with hysterectomy (P < 0.001). The trial sequential analysis indicated that the cumulative number of patients failed to meet the required sample size (number of patients).
CONCLUSIONS: The prognosis for patients with microinvasive cervical adenocarcinoma is excellent. Fertility preservation is at least appropriate for young women with stage IA1 adenocarcinoma. Further studies are still warranted to evaluate the safety of this procedure in managing patients with microinvasive cervical adenocarcinoma.

Entities:  

Keywords:  Cervical cancer; Fertility preservation; Microinvasive adenocarcinoma; Safety

Mesh:

Year:  2018        PMID: 29876746     DOI: 10.1007/s00404-018-4799-0

Source DB:  PubMed          Journal:  Arch Gynecol Obstet        ISSN: 0932-0067            Impact factor:   2.344


  1 in total

1.  Oncologic and obstetric outcomes after conization for adenocarcinoma in situ or stage IA1 cervical cancer.

Authors:  Xiaoyu Wang; Yalan Bi; Huanwen Wu; Ming Wu; Lei Li
Journal:  Sci Rep       Date:  2020-11-16       Impact factor: 4.379

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.